ICOS critically regulates the expansion and function of inflammatory human Th17 cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsJames L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
Life of this patent
Estimating the term…
Abstract
The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
Claims30
An ex vivo composition comprising a first agent that is capable of providing a primary activation signal to a T cell, a second agent that is capable of specifically binding and activating ICOS on said T cell, and a Th-17 polarizing agent selected from the group consisting of IL-1β, IL-6, neutralizing anti-IFNγ, anti-IL-4, and any combination thereof.
Dependencies are inferred from the claim text.